Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 15/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | KMO | O15229 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23909024 | 0.93 | S1PR2 (0.59) | S1PR2KCNH2KMONPC1P2RX3 | |
| SCHEMBL23914587 | 0.91 | S1PR2 (0.50) | S1PR2KCNH2KMOP2RX3 | |
| SCHEMBL23914568 | 0.85 | S1PR2 (0.58) | S1PR2KCNH2KMOP2RX3 | |
| SCHEMBL23966546 | 0.83 | S1PR2 (0.56) | S1PR2KCNH2KMOP2RX3 | |
| SCHEMBL23914864 | 0.82 | S1PR2 (0.43) | S1PR2KCNH2NPC1DGAT1 | |
| SCHEMBL23915546 | 0.76 | S1PR2 (0.41) | S1PR2NPC1DGAT1 | |
| SCHEMBL23914598 | 0.75 | KMO (0.39) | KMOP2RX3 | |
| SCHEMBL23915483 | 0.75 | S1PR2 (0.85) | S1PR2KCNH2P2RX3 | |
| SCHEMBL23909068 | 0.75 | KMO (0.37) | KMO | |
| SCHEMBL23909037 | 0.75 | NPC1 (0.44) | S1PR2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
| CN-110869359-A | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis | 加拉帕戈斯股份有限公司 | 2020-03-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | S1PR2 3/4885KCNH2 1865/4885KMO 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.